• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Emergency

Biomarkers obtained in the ED show limited utility in predicting pneumonia severity in children

byAlex Gipsman, MDandCordelia Ross
May 13, 2020
in Emergency, Infectious Disease, Pediatrics, Pulmonology
Reading Time: 2 mins read
Lefamulin noninferior to moxifloxacin for community-acquired pneumonia
Share on FacebookShare on Twitter

1. In a study of children with community acquired pneumonia, initial biomarker levels (C-reactive protein, white blood cell count, procalcitonin, absolute neutrophil count) were similar across illness severities.

2. Higher C-reactive protein and procalcitonin levels were predictive of specific severe outcomes, including empyema requiring chest drainage and septic shock.

Evidence Rating Level: 2 (Good)

Study Rundown: Community acquired pneumonia (CAP) is one of the most common conditions treated by pediatricians, yet predicting disease severity and prognosis is often difficult at the initial presentation. Previous studies on adults indicate that the biomarkers C-reactive protein (CRP), white blood cell (WBC) count, absolute neutrophil count (ANC), and procalcitonin may be associated with disease severity. Authors of this prospective cohort study evaluated whether the same was true in children aged 3 months to 18 years with suspected CAP who presented to the emergency department (ED). In the group of 477 children included in the analysis, there were no statistical differences in median WBC count, CRP level, ANC, or procalcitonin level across 4 different categories of disease severity. However, when specific outcomes were examined, CRP and procalcitonin levels were higher in those developing complicated pneumonia requiring chest tube placement and sepsis requiring vasoactive medications. Additionally, all biomarkers had high negative predictive values (NPV) in differentiating severe from non-severe disease and may therefore be useful in ruling out severe outcomes. Although this was a single center study which potentially limits its generalizability, it was larger than most previous studies examining biomarkers in CAP. Overall, the findings suggest that these biomarkers are generally not helpful in discriminating children with CAP who will go on to develop more severe outcomes from those who will not.

Click to read the study, published today in Pediatrics 

Relevant Reading: Predicting severe pneumonia outcomes in children

RELATED REPORTS

2 Minute Medicine Rewind July 6, 2026

Use of procalcitonin in neonatal late-onset sepsis may reduce the duration of antibiotic therapy without increase in mortality

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

In-Depth [prospective cohort]: This prospective cohort study included 477 children aged 3 months to 18 years (mean age 5.6 years, 52.6% male, 67% white) over a 4-year period who presented to the ED with signs and symptoms of lower respiratory tract infection (LRTI), had focal findings on chest x-ray (CXR) indicative of CAP, and had blood drawn. Children with immunocompromising or chronic medical conditions predisposing them to severe or recurrent pneumonia were excluded from the study. The primary outcome was disease severity, categorized as mild, mild-moderate, moderate-severe, and severe. Overall, median WBC count (P=0.24), ANC (P=0.26), CRP level (P=0.6), and procalcitonin level (P=0.21) were not associated with disease severity. However, all exhibited NPVs above 0.90 for the selected threshold values, making them helpful in ruling out severe disease. In models adjusted for age, antibiotic receipt before arrival, fever duration, and viral pathogen detection, CRP was modestly associated with disease severity (mild vs. more severe disease, OR 1.19, 95% CI 1.04-1.35). When individual outcomes were examined, CRP and procalcitonin levels were moderately associated with development of complicated pneumonia, infections requiring chest drainage, or septic shock.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: absolute neutrophil countbiomarkersc-reactive protein (CRP)community acquired pneumoniapneumoniaprocalcitoninwhite blood cell count
Previous Post

#VisualAbstract: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Next Post

#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

RelatedReports

Obstetric scoring systems overestimate cases of severe sepsis
All Specialties

2 Minute Medicine Rewind July 6, 2026

July 7, 2026
Obstetric scoring systems overestimate cases of severe sepsis
Emergency

Use of procalcitonin in neonatal late-onset sepsis may reduce the duration of antibiotic therapy without increase in mortality

May 28, 2026
Prescription of antibiotics for acute respiratory infections increasing
Infectious Disease

Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia

April 13, 2026
Brain lesions on MRI linked with subsequent increased stroke risk
Emergency

Two plasma-based biomarkers may accurately predict positive CT head scans in traumatic brain injury

March 22, 2026
Next Post
#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

Nivolumab may be effective in platinum-resistant ovarian cancer

Degarelix may be a treatment option for pedophilic disorder

#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19

#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer
  • A machine-learning diet score identifies eating patterns associated with lower aging-related mortality
  • Deep-learning model achieved high diagnostic performance for detecting cardiac enlargement using electrocardiograms
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.